The ArtixASCEND Study

Inclusion Criteria:

• Age ≥ 18 years

• Acute symptom duration ≤ 14 days

• Lower limb arterial occlusion below inguinal ligament

• Target lesion in native vessel

• Target vessel size between 3 mm and 8 mm by visual estimation

• Rutherford category I, IIa, or IIb

• Informed consent is obtained from either patient or legally authorizedrepresentative (LAR) per Institutional Review Board/Ethics Committee requirements

Exclusion Criteria:

• Life expectancy < 6 months

• Prior major amputation in the target limb

• Prior minor amputation in the target limb that is not completely healed or cannotbear weight

• Non-thrombotic occlusion secondary to dissection, vasculitis, or target vesseltrauma

• Treatment of the index event in the target vessel with any other endovascularthrombectomy/aspiration or open surgical method prior to Artix procedure

• Part of a vulnerable population (e.g., currently pregnant, breastfeeding orincarcerated) per local definitions

• Known sensitivity to radiographic contrast agents that, in the Investigator'sopinion, cannot be adequately pre-treated

• Unable to tolerate antiplatelet therapy

• Inability to anticoagulate the patient with heparin, enoxaparin or other parenteralantithrombin, or known to have uncorrected bleeding disorders (e.g.,gastro-intestinal ulcer, menorrhagia, liver failure, heparin-inducedthrombocytopenia (HIT))

• Any condition for which, in the opinion of the Investigator, participation would notbe in the best interest of the subject (e.g., contraindication to use of Artix perlocal approved labeling, compromise the well-being or that could prevent, limit, orconfound the protocol-specified assessments)

• Current participation in another drug or device study that, in the investigator'sopinion, would interfere with participation in this study